Childrens Allergy Solution
NDC Package 69676-0074-9
Package Information
Childrens Allergy (diphenhydramine hcl) solution is usestemporarily relieves these symptoms due to hay fever or other upper respiratory allergies:runny nosesneezingitchy, watery eyesitching of the nose or throat. This formulation utilizes a solution delivery system. Marketed by Genexa Inc., this product is identified by NDC 69676-0074 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 1049906 - diphenhydrAMINE HCl 12.5 MG in 5 mL Oral Solution
- RxCUI: 1049906 - diphenhydramine hydrochloride 2.5 MG/ML Oral Solution
- RxCUI: 1049906 - diphenhydramine HCl 12.5 MG per 5 ML Oral Solution
- RxCUI: 1049906 - diphenhydramine hydrochloride 25 MG per 10 ML Oral Solution
- RxCUI: 1049906 - diphenhydramine hydrochloride 50 MG per 20 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69676 - Genexa Inc.
- 69676-0074 - Childrens Allergy
- 69676-0074-9 - 1 BOTTLE, PLASTIC in 1 CARTON / 118 mL in 1 BOTTLE, PLASTIC
- 69676-0074 - Childrens Allergy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69676-0074-9 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 118 ml in 1 bottle, plastic of Childrens Allergy, a human over the counter drug labeled by Genexa Inc.. This solution is formulated for oral use and contains diphenhydramine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genexa Inc. on April 26, 2022. The current certification is valid through December 31, 2026.
How is this Genexa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69676007409. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.